 |
市場調査レポート
商品コード
1461510
バイオ医薬品の世界市場規模、シェア、成長分析、製品タイプ別、用途別、最終用途別 - 産業予測、2024年～2031年Global Biopharmaceuticals Market Size, Share, Growth Analysis, By By Product type(Monoclonal Antibodies, Gene Therapies), By Application(Oncology, Inflammatory Diseases), By End-use(Health And Care, Biopharma Companies) - Industry Forecast 2024-2031 |
||||||
| バイオ医薬品の世界市場規模、シェア、成長分析、製品タイプ別、用途別、最終用途別 - 産業予測、2024年～2031年 |
|
出版日: 2024年04月05日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のバイオ医薬品市場は、2022年に約3億7,787万米ドルとなり、予測期間中（2024年～2031年）にCAGR7.80%を記録することにより、2023年の4億734万米ドルから上昇し、2031年末までには7億4,287万米ドルに達すると予測されています。
バイオ医薬品企業は、他のバイオ医薬品企業に包装や医薬品製造などの受託サービスを提供することで、大規模なバイオ医薬品企業が製造プロセスを合理化し、創薬やマーケティングに集中できるようにしています。小規模なバイオテクノロジー企業は、社内生産能力に限界があるため、しばしば充填・仕上げ製造を外注し、設備投資の削減に貢献しています。バイオテクノロジーに由来するバイオ医薬品は、生物学的由来から直接抽出されたタンパク質や核酸を利用するもので、主にトランスジェニック生物として知られる遺伝子組み換え動植物を含む生体から抽出されますが、この方法は依然として論争の的で実験的なものです。承認されたバイオ医薬品の中で特筆すべきは遺伝子組換えヒト・インスリンで、現在300種類近い製品が販売されています。市場成長の促進力となっているのは、高齢化、ヘルスケアに対する意識の高まり、医療費の上昇といった要因であり、現在進行中の研究開発と新型バイオ医薬品の承認が市場拡大をさらに促進すると期待されています。とはいえ、業界は大きな課題に直面しており、特にこれらの医薬品は高コストであるため、事業の持続可能性を確保するためには大幅なコスト削減が必要です。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
バイオ医薬品の世界市場：製品タイプ別
- 市場概要
- モノクローナル抗体
- 遺伝子治療
- 血栓溶解薬・抗凝固薬
- 組み換えタンパク質
バイオ医薬品の世界市場：用途別
- 市場概要
- 腫瘍学
- 炎症性疾患
- 心臓病学
- 神経学
- 自己免疫疾患
- 代謝障害
- ホルモン障害
- その他
バイオ医薬品の世界市場：最終用途別
- 市場概要
- 健康・ケア
- バイオ医薬品企業
- 診断ラボ
- 臨床研究センター
- 臨床研究機関（CRO）
- その他
バイオ医薬品の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Pfizer, Inc.
- F. Hoffmann-La Roche AG
- Johnson & Johnson Services, Inc.
- Sanofi
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Biogen Idec
- Bayer AG
- Eli Lilly and Company
- Novartis AG
Global Biopharmaceuticals Market was valued around USD 377.87 million in 2022 and is expected to rise from USD 407.34 million in 2023 to reach USD 742.87 million by the end of 2031, by recording a CAGR of 7.80% during the forecast period (2024-2031).
A biopharmaceutical company offers contract services to other biopharmaceutical firms, encompassing packaging and drug manufacturing, thereby allowing larger biopharmaceutical entities to streamline their manufacturing processes and focus on drug discovery and marketing. Small biotechnology companies often outsource fill and finish manufacturing due to limited in-house production capacity, aiding in reducing capital expenditures. Biopharmaceuticals, derived from biotechnology, utilize proteins and nucleic acids extracted directly from biological sources, primarily living organisms including genetically modified plants and animals known as transgenic organisms, although this method remains contentious and experimental. Notable among approved biopharmaceuticals is recombinant human insulin, with nearly 300 such products currently available. Market growth is driven by factors such as an aging population, increased healthcare awareness, and rising healthcare costs, with ongoing research and development and approval for newer biopharmaceutical products expected to further propel market expansion. Nevertheless, the industry faces significant challenges, notably the high cost of these drugs, necessitating substantial reduction to ensure business sustainability.
Top-down and bottom-up approaches were used to estimate and validate the size of the global biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biopharmaceuticals Market Segmental Analysis
The global biopharmaceuticals market is segmented on the basis of product type, application, end use, and region. With respect to segmentation by product type, the market is segmented into the Monoclonal Antibodies, Gene Therapies, Thrombolytics and Anticoagulants, and Recombinant Protein. Based on classification by application, the market is categorized into Oncology, Inflammatory Diseases, Cardiology, Neurology, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, and Others. With respect to categorization by end use, the market is grouped into Health and Care, Biopharma Companies, Diagnostic Labs, Clinical Research Institute, Clinical Research Organizations (CROs), and Others. Region wise, the market is widespread into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.
Drivers of the Global Biopharmaceuticals Market
Globally, chronic illnesses like cancer, diabetes, and heart disease pose significant threats to health and well-being, with the World Health Organization projecting cancer to be responsible for nearly one-sixth of all deaths by 2020. Biopharmaceuticals leveraging protein-based therapies have emerged as effective treatments for various cancers, yet challenges persist due to factors such as increased tobacco usage, unhealthy dietary habits, excessive alcohol consumption, and sedentary lifestyles. Cardiovascular disease, a leading cause of mortality, claims lives every second in the United States alone, spurring innovation in the field, exemplified by companies like Invizius and 3P Biopharmaceuticals developing groundbreaking technologies to aid cardiovascular patients undergoing hemodialysis. With the prevalence of chronic diseases on the rise globally, the biopharmaceutical market is poised for significant expansion between 2024 and 2031.
Restraints in the Global Biopharmaceuticals Market
Due to the combination of low incomes and the heavy burden of healthcare expenses, individuals in developing nations face significant barriers in affording biomedicines and therapies, potentially hindering market expansion in the foreseeable future. According to the United Nations Development Program, as of 2020, 1.3 billion people, equivalent to 22% of the global population, live in poverty, limiting their access to adequate healthcare services due to financial constraints. Additionally, lacking robust healthcare infrastructure, half of the world's population is unable to avail themselves of essential medical facilities, as reported by the World Health Organization. These challenges collectively impact the biopharmaceuticals market, posing considerable difficulties for its growth trajectory.
Market Trends of the Global Biopharmaceuticals Market
The rapid growth of the biopharmaceuticals market is predominantly fueled by the effective utilization of monoclonal antibodies and their derivatives in therapeutic treatments. Various ailments such as cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases have benefited from these antibodies' therapeutic potential. The global healthcare systems have been under immense pressure due to the COVID-19 pandemic, prompting relentless efforts from researchers worldwide to address this escalating challenge. Consequently, there's an anticipated surge in demand for COVID-19-specific monoclonal antibodies to mitigate the impact of the pandemic.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Biopharmaceuticals Market by By Product type
- Market Overview
- Monoclonal Antibodies
- Gene Therapies
- Thrombolytics and Anticoagulants
- Recombinant Protein.
Global Biopharmaceuticals Market by Application
- Market Overview
- Oncology
- Inflammatory Diseases
- Cardiology
- Neurology
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders
- and Others
Global Biopharmaceuticals Market by End-use
- Market Overview
- Health And Care
- Biopharma Companies
- Diagnostic Labs
- Clinical Research Institute
- Clinical Research Organizations (CROs)
- and Others
Global Biopharmaceuticals Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Idec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
